TW200942614A - Composition for modulating stem cell growth - Google Patents

Composition for modulating stem cell growth

Info

Publication number
TW200942614A
TW200942614A TW098105222A TW98105222A TW200942614A TW 200942614 A TW200942614 A TW 200942614A TW 098105222 A TW098105222 A TW 098105222A TW 98105222 A TW98105222 A TW 98105222A TW 200942614 A TW200942614 A TW 200942614A
Authority
TW
Taiwan
Prior art keywords
composition
stem cell
cell growth
modulating
modulating stem
Prior art date
Application number
TW098105222A
Other languages
English (en)
Chinese (zh)
Inventor
Ryuji Ueno
Sachiko Kuno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of TW200942614A publication Critical patent/TW200942614A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • C07C53/134—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW098105222A 2008-02-19 2009-02-19 Composition for modulating stem cell growth TW200942614A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2971308P 2008-02-19 2008-02-19

Publications (1)

Publication Number Publication Date
TW200942614A true TW200942614A (en) 2009-10-16

Family

ID=40602552

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098105222A TW200942614A (en) 2008-02-19 2009-02-19 Composition for modulating stem cell growth

Country Status (16)

Country Link
US (2) US8871752B2 (https=)
EP (2) EP2656845A1 (https=)
JP (1) JP2011512323A (https=)
KR (1) KR20100119803A (https=)
CN (2) CN104248638A (https=)
AR (1) AR073158A1 (https=)
AU (1) AU2009216067B2 (https=)
BR (1) BRPI0907831A2 (https=)
CA (1) CA2715486A1 (https=)
IL (1) IL207652A0 (https=)
MX (1) MX2010009131A (https=)
NZ (1) NZ587348A (https=)
RU (1) RU2010138603A (https=)
TW (1) TW200942614A (https=)
WO (1) WO2009104807A1 (https=)
ZA (1) ZA201006125B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2408444A4 (en) * 2009-03-19 2012-09-26 Fate Therapeutics Inc COMPOSITIONS WITH CYCLIC AMP AMPLIFIERS AND / OR EP LIGANDS, AND METHOD FOR THEIR PRODUCTION AND USE
US8569279B2 (en) 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
AU2010253720A1 (en) * 2009-05-27 2011-12-08 Osaka University Pharmaceutical composition comprising prostaglandin derivatives for use in modulating claudin mediated functions and in the treatment of dermatological disorders
KR101171912B1 (ko) 2010-11-29 2012-08-07 기아자동차주식회사 밸브브릿지 일체형 가변 밸브 액츄에이터
US10111907B2 (en) 2011-12-02 2018-10-30 Fate Therapeutics, Inc. Methods of treating ischemia
EP3785767A1 (en) 2011-12-02 2021-03-03 Fate Therapeutics, Inc. Enhanced stem cell composition
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
US20140371304A1 (en) * 2013-06-13 2014-12-18 Sucampo Ag Method for suppressing tumorigenicity of stem cells
EP3423067B1 (en) * 2016-03-04 2025-07-23 The Board of Trustees of the Leland Stanford Junior University Inhibitors of 15-hydroxyprostaglandin dehydrogenase for muscle regeneration
US9918994B2 (en) 2016-03-04 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
WO2018227138A1 (en) 2017-06-09 2018-12-13 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for preventing or treating muscle conditions
RU2686718C1 (ru) * 2018-03-12 2019-04-30 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство, стимулирующее функции мезенхимальных клеток-предшественников in vitro

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) * 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
TW224942B (https=) * 1990-04-04 1994-06-11 Adka Ueno Kk
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
WO1997047595A1 (en) * 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Endothelin antagonist
TWI284535B (en) 2000-03-24 2007-08-01 Sucampo Ag Apoptosis inhibitor
US20070204351A1 (en) 2004-01-14 2007-08-30 Davidson Bruce P Direct differentiation of cardiomyocytes from human embryonic stem cells
US8202909B2 (en) 2005-01-27 2012-06-19 Sucampo Ag Method for treating central nervous system disorders
JP4557288B2 (ja) * 2005-01-28 2010-10-06 アイシン・エィ・ダブリュ株式会社 画像認識装置及び画像認識方法、並びにそれを用いた位置特定装置、車両制御装置及びナビゲーション装置
KR20160120809A (ko) * 2005-03-04 2016-10-18 수캄포 아게 말초 혈관 질환 치료를 위한 방법 및 조성물
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
EP3424507A1 (en) 2006-03-24 2019-01-09 Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
US9394520B2 (en) 2006-12-08 2016-07-19 University Of Rochester Expansion of hematopoietic stem cells
US20080207759A1 (en) * 2007-02-27 2008-08-28 Sucampo Ag Method for protecting mitochondria
FI20075417A0 (fi) * 2007-06-05 2007-06-05 Marjo-Riitta Suuronen Koostumuksia ja menetelmiä alkion kantasolujen kasvatukseen

Also Published As

Publication number Publication date
JP2011512323A (ja) 2011-04-21
ZA201006125B (en) 2011-05-25
US20090209643A1 (en) 2009-08-20
IL207652A0 (en) 2010-12-30
MX2010009131A (es) 2010-12-06
KR20100119803A (ko) 2010-11-10
EP2303278A1 (en) 2011-04-06
CN102014921A (zh) 2011-04-13
AU2009216067B2 (en) 2014-02-13
NZ587348A (en) 2012-04-27
CA2715486A1 (en) 2009-08-27
AU2009216067A1 (en) 2009-08-27
EP2656845A1 (en) 2013-10-30
RU2010138603A (ru) 2012-03-27
CN104248638A (zh) 2014-12-31
US8871752B2 (en) 2014-10-28
WO2009104807A1 (en) 2009-08-27
US20150005381A1 (en) 2015-01-01
BRPI0907831A2 (pt) 2017-04-11
AR073158A1 (es) 2010-10-20

Similar Documents

Publication Publication Date Title
TW200942614A (en) Composition for modulating stem cell growth
EP4296270A3 (en) A composition comprising stem cell cultures
MX356756B (es) Células madre pluripotentes en microportadores.
MY159971A (en) Multipotent/pluripotent cells and methods
WO2010111422A3 (en) Induced pluripotent stem cell generation using two factors and p53 inactivation
MX2010000348A (es) Cultivo de celulas madre pluripotentes individuales.
WO2009092087A3 (en) Selective differentiation, identification, and modulation of human th17 cells
AU2007230902A8 (en) Method to modulate hematopoietic stem cell growth
WO2007101130A3 (en) Compositions and methods useful for culturing differentiable cells
EP2046946B8 (en) Pluripotent stem cell culture
WO2012003479A3 (en) Methods for culturing undifferentiated cells using sustained release compositions
GB2477698B (en) Methods for conducting cellular assays
WO2010048417A3 (en) Perfusion bioreactors, cell culture systems, and methods for production of cells and cell-derived products
EP4368701A3 (en) Feeder-free culture system
GB2454386A (en) Method for stem cell culture and cells derived therefrom
WO2012061082A3 (en) Chromobacterium bioactive compositions and metabolites
PH12014501019A1 (en) Kit comprising serum replacement and labile factors
SG148171A1 (en) Methods of proliferating stem cells
IL246057A0 (en) Peptide-presenting surfaces for long-term culture of multipotential cells
MX2010007945A (es) Preparacion y transplante de celulas de isletas pancreaticas.
CA2830600C (en) Compositions and methods for enhancing the pluripotency of stem cells
IN2012DN02760A (https=)
MX2012002013A (es) Moduladores de activador del factor de crecimiento de hepatocitos.
WO2011143400A3 (en) Method and composition for inducing human pluripotent stem cells
PH12014500304A1 (en) Enzyme system